









Markets
/
Stocks
/
nasdaq-vir
/

Vir Biotechnology Inc

VIR

5.180USD

+0.380+7.92%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

719.43MMarket Cap

LossP/E TTM



Vir Biotechnology Inc

5.180

+0.380+7.92%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company shows weak stock market performance, in line with its weak fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

124 / 506

Overall Ranking

239 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Buy

Current Rating

17.222

Target Price

+258.80%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.

Growing

The company is in a growing phase, with the latest annual income totaling USD 74.20M.

Overvalued

The company’s latest PE is -1.29, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 124.85M shares, decreasing 10.90% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 13.20M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 5.86, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 1.21M, representing a year-over-year decrease of 60.52%, while its net profit experienced a year-over-year decrease of 19.82%.

Score

Industry at a Glance

Previous score

5.86

Change



Financials

6.96

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.72

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.74

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.20, which is 15.55% below the recent high of -1.38 and -102.31% above the recent low of -2.42.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 124/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 8.40, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Vir Biotechnology Inc is 15.00, with a high of 31.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

8.40

Change

Support & Resistance

No Data

Analyst Rating

Based on 10 analysts

Buy

Current Rating

17.222

Target Price

+258.80%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Vir Biotechnology Inc

VIR

CRISPR Therapeutics AG

CRSP

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 5.85, which is lower than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 5.66 and the support level at 4.09, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.85

Change

0.32

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.006

Neutral

RSI(14)

54.636

Neutral

STOCH(KDJ)(9,3,3)

39.273

Buy

ATR(14)

0.301

High Vlolatility

CCI(14)

-5.754

Neutral

Williams %R

51.577

Neutral

TRIX(12,20)

0.243

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

4.926

Buy

MA10

5.069

Buy

MA20

4.966

Buy

MA50

5.038

Buy

MA100

5.134

Buy

MA200

6.604

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 89.88%, representing a quarter-over-quarter decrease of 1.55%. The largest institutional shareholder is The Vanguard, holding a total of 13.20M shares, representing 9.50% of shares outstanding, with 0.68% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

SB Investment Advisers (UK) Limited

16.68M

BlackRock Institutional Trust Company, N.A.

14.37M

-2.04%

The Vanguard Group, Inc.

Star Investors

12.78M

-2.47%

ARCH Venture Partners

12.92M

GSK plc

8.55M

State Street Global Advisors (US)

5.73M

+12.86%

Scangos (George A)

3.78M

-12.72%

Citadel Advisors LLC

1.62M

+496.18%

Dimensional Fund Advisors, L.P.

2.68M

+40.14%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.12, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.25. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.